Danaher Corporation (NYSE:DHR) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its position in shares of Danaher Corporation (NYSE:DHR) by 5.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,641,415 shares of the conglomerate’s stock after selling 150,593 shares during the period. Dimensional Fund Advisors LP owned approximately 0.37% of Danaher worth $541,480,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. GHP Investment Advisors Inc. increased its holdings in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC acquired a new stake in Danaher in the 4th quarter valued at approximately $27,000. Sierra Ocean LLC increased its holdings in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in Danaher in the 1st quarter valued at approximately $31,000. Finally, Dunhill Financial LLC increased its holdings in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 67 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DHR. Royal Bank Of Canada reiterated an “outperform” rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. JPMorgan Chase & Co. dropped their target price on shares of Danaher from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Tuesday, April 22nd. Leerink Partners boosted their price target on shares of Danaher from $225.00 to $230.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 23rd. Evercore ISI dropped their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Finally, Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target for the company in a research note on Friday, July 11th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $247.61.

Danaher Price Performance

Danaher stock opened at $210.43 on Friday. The stock has a market cap of $150.68 billion, a P/E ratio of 44.77, a price-to-earnings-growth ratio of 2.92 and a beta of 0.73. The company has a fifty day simple moving average of $199.64 and a 200-day simple moving average of $200.12. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.72 EPS. Equities analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.